0
0
Home > Pharmaceuticals >  Oncology >  Brain Cancer – Epidemiology Forecast to 2030

Brain Cancer – Epidemiology Forecast to 2030

Primary brain cancer (ICD-10 = C70, C71, C72) is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (National Cancer Institute, 2021). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors (American Brain Tumor Association, 2020). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth. Only malignant tumors are designated as cancer (National Cancer Institute, 2021).

The report includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of brain cancer segmented. The diagnosed incident cases of brain cancer are further segmented by sex, age (all ages), and type (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and others). Further, the diagnosed incident cases of glioblastoma are also segmented by grade (low-grade glioma and high-grade glioma), origin (primary and secondary), biomarkers (MGMT unmethylated, MGMT methylated, EGFR VIII positive, and EGFR amplification positive), and mutations (IDH1/IDH2 mutation, TERT promotor mutation, BRAF-V600E mutation, and NTRK mutation).

The following data describes epidemiology of brain cancer. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of brain cancer from 121,646 cases in 2020 to 147,148 cases in 2030, at an AGR of 2.10% over the forecast period. The five-year diagnosed prevalent cases of brain cancer in the 8MM are expected to increase from 243,850 cases in 2020 to 303,136 cases in 2030, with an AGR of 2.43% during the forecast period. Brain cancer is known to be more common in men than in women and shows a bimodal distribution, with an increased incidence among children and an increasing incidence with age. This is shown in GlobalData’s forecast for the diagnosed incident cases from 2020–2030 in the 8MM.

Scope

The Brain Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of brain cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).

The report includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of brain cancer segmented. The diagnosed incident cases of brain cancer are further segmented by sex, age (all ages), and type (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and others). Further, the diagnosed incident cases of glioblastoma are also segmented by grade (low-grade glioma and high-grade glioma), origin (primary and secondary), biomarkers (MGMT unmethylated, MGMT methylated, EGFR VIII positive, and EGFR amplification positive), and mutations (IDH1/IDH2 mutation, TERT promotor mutation, BRAF-V600E mutation, and NTRK mutation). The model associated with this report additionally provides diagnosed incident cases of glioblastoma by recurrence.

The brain cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Brain Cancer Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global brain cancer market.

Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

Understand magnitude of brain cancer population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Brain Cancer: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Diagnosed Incident Cases of Brain Cancer

2.4.4 Diagnosed Incident Cases of Brain Cancer by Type

2.4.5 Diagnosed Incident Cases of Glioblastoma by Grade

2.4.6 Diagnosed Incident Cases of Glioblastoma by Origin

2.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

2.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations

2.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

2.5 Epidemiological Forecast for Brain Cancer (2020–2030)

2.5.1 Diagnosed Incident Cases of Brain Cancer

2.5.2 Age-Specific Diagnosed Incident Cases of Brain Cancer

2.5.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer

2.5.4 Diagnosed Incident Cases of Brain Cancer by Type

2.5.5 Diagnosed Incident Cases of Glioblastoma by Grade

2.5.6 Diagnosed Incident Cases of Glioblastoma by Origin

2.5.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

2.5.8 Diagnosed Incident Cases of Glioblastoma by Mutations

2.5.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with Brain Cancer

List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of Brain Cancer, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, Both Sexes, N, All Ages, 2020 and 2030

Figure 3: 8MM, Diagnosed Incidence of Brain Cancer, Men, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 4: 8MM, Diagnosed Incidence of Brain Cancer, Women, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 5: 8MM, Sources Used to Forecast Diagnosed Incident Cases Brain Cancer (ICD-10 = C70, C71, C72)

Figure 6: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer (ICD-10 = C70, C71, C72)

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer (ICD-10 = C70, C71, C72) by Type

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Grade (WHO Grading System)

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Origin

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Biomarkers and Mutations

Figure 11: 8MM, Diagnosed Incident Cases of Brain Cancer, N, Both Sexes, All Ages, 2020

Figure 12: 8MM, Diagnosed Incident Cases of Brain Cancer by Age, N, Both Sexes, 2020

Figure 13: 8MM, Diagnosed Incident Cases of Brain Cancer by Sex, N, All Ages, 2020

Figure 14: 8MM, Diagnosed Prevalent Cases of Brain Cancer by Type, N, Both Sexes, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases of Glioblastoma by Grade, N, Both Sexes, All Ages, 2020

Figure 16: 8MM, Diagnosed Incident Cases of Glioblastoma by Origin, N, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Biomarkers, N, Both Sexes, All Ages, 2020

Figure 18: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Mutations, N, Both Sexes, All Ages, 2020

Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, N, Both Sexes, All Ages, 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports